Cash, cash equivalents, marketable securities and deposits at the beginning of the period

185,757

223,440

202,865

Cash, cash equivalents, marketable securities and deposits at the end of the period

$ 184,121

$ 185,757

$ 209,972

*

During February 2015 we have made a one-time early payment of $9.6 million to the Israeli Office of Chief Scientist, representing the full balance of the contingent liability related to the NP-5 grants received. Upon making this payment, we have eliminated all future royalty obligations related to our anticipated NP-5 revenues and saved the associated future interest payments related to such obligations. This amount was excluded from the non-GAAP operating cash flow as it represents future royalty obligations.

**

Including unrealized gain (loss) on marketable securities, accumulated interest accretion and amortization of discount and premium on marketable securities.